Eman Al-Antary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eman Al-Antary has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Süreyya Savaşan
Division of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI 48201, USA
3 shared publications Avanti Gupte
Division of Hematology/Oncology, Children’s Hospital of Michigan, Pediatric Blood and Marrow Transplantation Program, Barbara Ann Karmanos Cancer Center, Detroit, USA
2 shared publications- Avanti Gupte
Pediatric Department, Children’s Hospital of Michigan, Detroit, MI 48201, USA
2 shared publications Janet Poulik
Pediatric Pathology Department
2 shared publicationsKanta Bhambhani
Children's Hospital of Michigan
2 shared publicationsMary Caverly
Division of Hematology/Oncology, Pediatric Blood and Marrow Transplantation Program, Barbara Ann Karmanos Cancer Center Children's Hospital of Michigan Detroit Michigan USA
2 shared publications
Latest Publications
- 10 September 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (8) , 429-435
Mixed Chimerism and Clinical Outcome of Hematopoietic Stem Cell Transplantation in Glanzmann Thrombasthenia: Experience on 2 Siblings and Literature Review
Glanzmann thrombasthenia (GT) is a rare autosomal recessive platelet disorder characterized by abnormalities in platelet aggregation, resulting from quantitative or qualitative defects in integrins αIIb and β3. Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative therapeutic approach for severe GT. In this report, we present 2 children with GT that underwent successful allo-HSCT, along with 2008 to 2022 data from the Center for International Blood and Marrow Transplant Research and a summary of the existing literature providing further evidence that allo-HSCT can be a curative approach that prevents severe and life-threatening bleeding in GT. Our cases empathize the importance of monitoring flow cytometric platelet integrin αIIb (GPIIb) and β3 (GPIIIa) detection in identifying potential late graft rejection, which is a more direct assessment of platelet populations, particularly in the case of pretransplant presence of platelet antiglycoprotein GPIIb/IIIa complex antibodies.
- 10 September 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (8) , 429-435
Mixed Chimerism and Clinical Outcome of Hematopoietic Stem Cell Transplantation in Glanzmann Thrombasthenia: Experience on 2 Siblings and Literature Review
Glanzmann thrombasthenia (GT) is a rare autosomal recessive platelet disorder characterized by abnormalities in platelet aggregation, resulting from quantitative or qualitative defects in integrins αIIb and β3. Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative therapeutic approach for severe GT. In this report, we present 2 children with GT that underwent successful allo-HSCT, along with 2008 to 2022 data from the Center for International Blood and Marrow Transplant Research and a summary of the existing literature providing further evidence that allo-HSCT can be a curative approach that prevents severe and life-threatening bleeding in GT. Our cases empathize the importance of monitoring flow cytometric platelet integrin αIIb (GPIIb) and β3 (GPIIIa) detection in identifying potential late graft rejection, which is a more direct assessment of platelet populations, particularly in the case of pretransplant presence of platelet antiglycoprotein GPIIb/IIIa complex antibodies.
- Open Access
- 26 March 2024
- Published by Wolters Kluwer Health in JAPA Academy Journal
- Vol. 2 (1)
Hemophagocytic Lymphohistiocytosis: an updated overview and management approach in the critical care setting
Hemophagocytic lymphohistiocytosis (HLH) constitutes a rare and potentially life-threatening immunological syndrome. It manifests in both primary (genetic) and secondary (acquired) forms, exhibiting a diverse range of clinical and laboratory features, thereby posing challenges to accurate diagnosis, particularly within critical care settings. Early identification and intervention are of vital importance for improving patient survival. This article comprehensively explores the existing literature, encompassing the classification, pathophysiology, and clinical presentation of HLH. Special emphasis is placed on identifying prognostic factors, organ failure, and associated complications. Moreover, a detailed narrative of proposed management strategies, including immuno- and myelosuppressive options, is presented. Further research directions are suggested to enhance the understanding and treatment of this complex disorder.
- 26 March 2024
- Published by Wolters Kluwer Health in JAPA Academy Journal
- Vol. 2 (1)
Open AccessHemophagocytic Lymphohistiocytosis: an updated overview and management approach in the critical care setting
Hemophagocytic lymphohistiocytosis (HLH) constitutes a rare and potentially life-threatening immunological syndrome. It manifests in both primary (genetic) and secondary (acquired) forms, exhibiting a diverse range of clinical and laboratory features, thereby posing challenges to accurate diagnosis, particularly within critical care settings. Early identification and intervention are of vital importance for improving patient survival. This article comprehensively explores the existing literature, encompassing the classification, pathophysiology, and clinical presentation of HLH. Special emphasis is placed on identifying prognostic factors, organ failure, and associated complications. Moreover, a detailed narrative of proposed management strategies, including immuno- and myelosuppressive options, is presented. Further research directions are suggested to enhance the understanding and treatment of this complex disorder.
- Open Access
- 11 March 2024
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 9 (2) , 82-86
An unusual association of deletion of SMARCB1 in a patient with intracranial yolk sac tumor: A case-report
- 11 March 2024
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 9 (2) , 82-86
Open AccessAn unusual association of deletion of SMARCB1 in a patient with intracranial yolk sac tumor: A case-report
- Open Access
- 31 January 2024
- Published by Wiley
Unusual presentation of Thrombotic Thrombocytopenic Purpra in a newly diagnosed pediatric patient with Systemic Lupus Erythematosus in the setting of MIS-C
The understanding of Coronavirus disease 2019 (COVID-19) immune dysregulation is evolving. Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with alternations in both innate and adaptive immunity, probably caused by a complex interplay of genetics and environmental exposure with various triggers. A rare hematological complication of SLE as well as recently reported in adult with COVID-19 is thrombotic thrombocytopenic purpura (TTP). We report a pediatric case with features suggestive of multisystem inflammatory syndrome in children (MIS-C) with coronary artery ectasia, TTP, autoimmune hemolytic anemia (AIHA) and thrombocytopenia with new onset SLE as well.
- 31 January 2024
- Published by Wiley
Open AccessUnusual presentation of Thrombotic Thrombocytopenic Purpra in a newly diagnosed pediatric patient with Systemic Lupus Erythematosus in the setting of MIS-C
The understanding of Coronavirus disease 2019 (COVID-19) immune dysregulation is evolving. Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with alternations in both innate and adaptive immunity, probably caused by a complex interplay of genetics and environmental exposure with various triggers. A rare hematological complication of SLE as well as recently reported in adult with COVID-19 is thrombotic thrombocytopenic purpura (TTP). We report a pediatric case with features suggestive of multisystem inflammatory syndrome in children (MIS-C) with coronary artery ectasia, TTP, autoimmune hemolytic anemia (AIHA) and thrombocytopenia with new onset SLE as well.
- Open Access
- 30 January 2024
- Published by Wiley
Recurrent Vincristine-induced Fever in a Child with Wilms tumor
Recurrent Vincristine-induced Fever in a Child with Wilms tumor
- 30 January 2024
- Published by Wiley
Open AccessRecurrent Vincristine-induced Fever in a Child with Wilms tumor
Recurrent Vincristine-induced Fever in a Child with Wilms tumor
- Open Access
Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Immune checkpoint inhibitors (ICIs) are a relatively new class of immunotherapy which bolsters the host immune system by “turning off the brakes” of effector cells (e.g., CTLA-4, PD-1, PD-L1). Although their success in treating adult malignancy is well documented, their utility in pediatric cancer has not yet been shown to be as fruitful. We review ICIs, their use in pediatric malignancies, and active pediatric clinical trials, exemplifying some of adult efforts that could be related to pediatric future trials and complications of ICI therapy. Through our review, we propose the consideration of ICI as standard therapy in lymphoma and various solid tumor types, especially in relapsed or refractory (R/R) disease. However, further studies are needed to demonstrate ICI effectiveness in pediatric leukemia.
Open AccessCheckpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Immune checkpoint inhibitors (ICIs) are a relatively new class of immunotherapy which bolsters the host immune system by “turning off the brakes” of effector cells (e.g., CTLA-4, PD-1, PD-L1). Although their success in treating adult malignancy is well documented, their utility in pediatric cancer has not yet been shown to be as fruitful. We review ICIs, their use in pediatric malignancies, and active pediatric clinical trials, exemplifying some of adult efforts that could be related to pediatric future trials and complications of ICI therapy. Through our review, we propose the consideration of ICI as standard therapy in lymphoma and various solid tumor types, especially in relapsed or refractory (R/R) disease. However, further studies are needed to demonstrate ICI effectiveness in pediatric leukemia.
- 14 July 2023
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91 (2) , 176-183
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape
- 14 July 2023
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91 (2) , 176-183
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape
- Open Access
The Impact of COVID-19 on Pediatric Malignancy Diagnosis and Treatment: Never the Same but Lessons Learned
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic affected the pediatric oncology population globally. Over the course of 2 years, increasing reports have been made to better understand this entity and its pathologic complications on these patients. The pandemic has allowed healthcare providers, hospital systems, and leading oncologic societies to quickly adapt and formulate new guidelines for the effective understanding, management, and treatment of patients with pediatric malignancy.
Open AccessThe Impact of COVID-19 on Pediatric Malignancy Diagnosis and Treatment: Never the Same but Lessons Learned
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic affected the pediatric oncology population globally. Over the course of 2 years, increasing reports have been made to better understand this entity and its pathologic complications on these patients. The pandemic has allowed healthcare providers, hospital systems, and leading oncologic societies to quickly adapt and formulate new guidelines for the effective understanding, management, and treatment of patients with pediatric malignancy.
- 14 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30137
Delayed but successful T‐cell immune reconstitution following umbilical cord blood transplantation conditioned with thymoglobulin alone in IL‐7Rα‐mutated SCID
- 14 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30137
Delayed but successful T‐cell immune reconstitution following umbilical cord blood transplantation conditioned with thymoglobulin alone in IL‐7Rα‐mutated SCID
- Open Access
- 3 October 2022
- Published by Wiley
Delayed but Successful T Cell Immune Reconstitution Following Umbilical Cord Blood Transplantation Conditioned with Thymoglobulin alone in IL-7Rα-mutated SCID
Delayed but Successful T Cell Immune Reconstitution Following Umbilical Cord Blood Transplantation Conditioned with Thymoglobulin alone in IL-7Rα-mutated SCID Eman T. Al-Antary, MD1,5, Mary Caverly, CPNP2, Steve Buck3, Sharat Chandra, MD4, Süreyya Savaşan, MD1-3, 5
- 3 October 2022
- Published by Wiley
Open AccessDelayed but Successful T Cell Immune Reconstitution Following Umbilical Cord Blood Transplantation Conditioned with Thymoglobulin alone in IL-7Rα-mutated SCID
Delayed but Successful T Cell Immune Reconstitution Following Umbilical Cord Blood Transplantation Conditioned with Thymoglobulin alone in IL-7Rα-mutated SCID Eman T. Al-Antary, MD1,5, Mary Caverly, CPNP2, Steve Buck3, Sharat Chandra, MD4, Süreyya Savaşan, MD1-3, 5